180 Life Sciences's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of 180 Life Sciences (ATNF) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: 180 Life Sciences vs Its Competitors
- TTM: Trailing 12-month revenue of 11M vs 466,058M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-49.3% annualized vs trailing 12 months), vs accelerating (+3.1%) for its tracked peer group.
- Profitability: Its -939.1% net margin compares with 12.0% for the peer group.
- Peer revenue share: 180 Life Sciences accounted for 0.0% of combined revenue among its tracked peer group.
- Peer differentiation: Revenue per employee of $2.69M compares with $1.01M for the peer group (2.7x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ATNF Sales vs. its Competitors, Q2 2026
With a net margin of -939.05 %, 180 Life Sciences reported lower profitability than its competitors (11.95 %).
180 Life Sciences generated 0.00 % of the combined sales of its peer group.
180 Life Sciences vs. its Competitors, Q2 2026
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across 180 Life Sciences and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| 180 Life Sciences Corp | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across 180 Life Sciences's competitor groups requires a Commercial License.
180 Life Sciences's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| 180 Life Sciences Corp | No | - | - | No |
| Competitors combined (111) | ||||
| High-Confidence Competitors (1) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ATNF Stock Performance relative to its Competitors
ATNF Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Ventyx Biosciences Inc | 282.9% | Outperformed |
| 2 | Damora Therapeutics Inc | 282.9% | Outperformed |
| 3 | Prelude Therapeutics Inc | 282.9% | Outperformed |
| 4 | Dianthus Therapeutics Inc | 282.9% | Outperformed |
| 5 | Precigen Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for 180 Life Sciences's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
180 Life Sciences's Comment on Competition and Industry Peers
Publicly Traded Peers of 180 Life Sciences Corp
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| 180 Life Sciences Corp | 120.15 | 10.77 |
| Johnson and Johnson | 663,585.20 | 97,929.00 |
| Beone Medicines Ltd | 552,467.82 | 6,128.24 |
| Abbvie Inc | 471,581.88 | 64,386.00 |
| Merck and Co Inc | 367,264.30 | 66,569.00 |
| Astrazeneca Plc | 259,526.30 | 58,739.00 |
| SUBTOTAL | 3,471,871.87 | 623,631.20 |
Sign in to see all competitors of 180 Life Sciences Corp.
Sources: 180 Life Sciences Corp's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on 180 Life Sciences Corp versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
180 Life Sciences's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Auxilium | Named by the company | 85% |
| Hebrew University of Jerusalem | Named by the company | 85% |
| Oxford | Named by the company | 85% |
| Medicines Co | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for 180 Life Sciences's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
180 Life Sciences's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Johnson and Johnson | Oncology 29.26 % |
| Merck and Co Inc | Pharmaceutical segment 88.88 % |
| Amgen Inc | Reportable 100.00 % |
| Pfizer Inc | U.S. Commercial Division 52.92 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for 180 Life Sciences Corp.
180 Life Sciences's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| 180 Life Sciences Corp | 120 | 2,692,742 | -147,122,114 |
| Johnson and Johnson | 663,585 | 695,518 | 149,411 |
| Beone Medicines Ltd | 552,468 | 510,686 | 54,642 |
| Abbvie Inc | 471,582 | 1,129,579 | 110,807 |
| Merck and Co Inc | 367,264 | 887,587 | 42,267 |
| Astrazeneca Plc | 259,526 | 706,847 | 123,141 |
| PEERS TOTAL | 3,471,752 | 1,013,417 | 138,636 |
Sign in to see all peers for 180 Life Sciences Corp.
180 Life Sciences's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Johnson and Johnson | United States 57.42 % |
| Beone Medicines Ltd | United States 51.69 % |
| Merck and Co Inc | EMEA 23.60 % |
| Pfizer Inc | United States 58.91 % |
| Vertex Pharmaceuticals Inc | United States 61.68 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for 180 Life Sciences Corp.
180 Life Sciences's Position in Industry Market Structure
Market-capitalization share and concentration across all 103 companies in 180 Life Sciences's industry classification, broader than the peer set above. Market cap in millions of $.180 Life Sciences ranks #0 of 103 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,294, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | American Express Company | 207,244 | 31.55 % |
| 2 | Nu Holdings Ltd | 61,219 | 9.32 % |
| 3 | Coinbase Global Inc | 51,945 | 7.91 % |
| 4 | Eason Technology Limited | 38,113 | 5.80 % |
| 5 | Strategy Inc | 1,234 | 5.2% |
| 6 | Federal National Mortgage Association Fannie Mae | 1,234 | 5.2% |
| 7 | Synchrony Financial | 1,234 | 5.2% |
| 8 | Circle Internet Group Inc | 1,234 | 5.2% |
| 9 | Sofi Technologies Inc | 1,234 | 5.2% |
| 10 | Bitmine Immersion Technologies Inc | 1,234 | 5.2% |
| 0 | 180 Life Sciences Corp | 150 | 0.00 % |
Market cap and industry share for the rest of 180 Life Sciences's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2025-08-15.
180 Life Sciences's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Miscellaneous Financial Services industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (80 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | - | 53.42 % (avg) | - |
| Operating Margin | -2,268.39 % | industry median | -2,253.9 pp |
| EBITDA Margin | -4,902.63 % | 2.15 % (avg) | -4,904.8 pp |
| Capital Intensity (Capex / Revenue) | 0.00 % | 4.86 % (avg) | -4.9 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
180 Life Sciences's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - |
| Return on Invested Capital | -0.49 % | -2.84 % | -21.81 % | -28.61 % | -28.00 % | -104.48 % | -47.23 % |
| P/E | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
180 Life Sciences's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,294 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.00 % vs industry average 4.86 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See 180 Life Sciences's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See 180 Life Sciences's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
180 Life Sciences's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
180 Life Sciences falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
180 Life Sciences's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Operating margin 2,253.9 points below the industry median.
- Return on equity 233.1 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-49.3% annualized vs trailing 12 months).
Opportunities
- A meaningful share of tracked competitors (34.30 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
180 Life Sciences's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| 180 Life Sciences Corp | 1.15 | 5.93 | 0.59 |
| Johnson and Johnson | 0.37 | 1.05 | 0.60 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Abbvie Inc | 0.16 | 0.75 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
Sign in to see all peers for 180 Life Sciences Corp.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
180 Life Sciences's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| 180 Life Sciences Corp | Q2 2026 | - | - |
| Johnson and Johnson | Q2 2026 | +6.6 % | -0.1 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Abbvie Inc | Q2 2026 | +10.2 % | +284.3 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| PEERS TOTAL | +7.3 % | +16.5 % |
Sign in to see all peers for 180 Life Sciences Corp.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
180 Life Sciences's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| 180 Life Sciences Corp | Q2 2026 | - | - |
| Johnson and Johnson | Q2 2026 | +5.5 % | +26.7 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Abbvie Inc | Q2 2026 | -1.3 % | +19.7 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
Sign in to see all peers for 180 Life Sciences Corp.
180 Life Sciences's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| 180 Life Sciences Corp | - | - | - |
| Johnson and Johnson | 10.60% | 13.30% | 25.74% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Abbvie Inc | 4.68% | 9.11% | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
Sign in to see all peers for 180 Life Sciences Corp.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
180 Life Sciences's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| 180 Life Sciences Corp | - | 11.15 |
| Johnson and Johnson | 31.48 | 6.78 |
| Beone Medicines Ltd | 834.09 | 90.15 |
| Abbvie Inc | 75.22 | 7.32 |
| Merck and Co Inc | 119.91 | 5.52 |
| Astrazeneca Plc | 25.38 | 4.42 |
| PEERS AVERAGE | 40.98 | 5.57 |
Sign in to see all peers for 180 Life Sciences Corp.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.